Literature DB >> 26883694

Clinical and Epidemiological Significance of Carbapenem Resistance in Acinetobacter baumannii Infections.

Ruthy Tal-Jasper1, David E Katz2, Nadav Amrami3, Dor Ravid3, Dori Avivi3, Ronit Zaidenstein4, Tsilia Lazarovitch5, Mor Dadon3, Keith S Kaye6, Dror Marchaim7.   

Abstract

Carbapenems are considered the treatment of choice for Acinetobacter baumannii infections. Many facilities implement preventive measures toward only carbapenem-resistant A. baumannii (CRAB). However, the independent role of the carbapenem resistance determinant on patient outcomes remains controversial. In a 6-year analysis of adults with A. baumannii bloodstream infection (BSI), the outcomes of 149 CRAB isolates were compared to those of 91 patients with carbapenem-susceptible A. baumannii In bivariable analyses, CRAB BSIs were significantly associated with worse outcomes and with a delay in the initiation of appropriate antimicrobial therapy (DAAT). However, in multivariable analyses, carbapenem resistance status was no longer associated with poor outcomes, while DAAT remained an independent predictor. The epidemiological significance of A. baumannii should not be determined by its resistance to carbapenems.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26883694      PMCID： PMC4862462          DOI： 10.1128/AAC.02656-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Treatment of Acinetobacter infections.

Authors:  Joel Fishbain; Anton Y Peleg
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

2.  The carbapenem-resistant Enterobacteriaceae score: a bedside score to rule out infection with carbapenem-resistant Enterobacteriaceae among hospitalized patients.

Authors:  Emily T Martin; Ryan Tansek; Vicki Collins; Kayoko Hayakawa; Odaliz Abreu-Lanfranco; Teena Chopra; Paul R Lephart; Jason M Pogue; Keith S Kaye; Dror Marchaim
Journal:  Am J Infect Control       Date:  2012-08-30       Impact factor: 2.918

3.  Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.

Authors:  John S Esterly; Milena Griffith; Chao Qi; Michael Malczynski; Michael J Postelnick; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 4.  Hospital-acquired infections due to gram-negative bacteria.

Authors:  Anton Y Peleg; David C Hooper
Journal:  N Engl J Med       Date:  2010-05-13       Impact factor: 91.245

5.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

6.  Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotics resistance, and patient age.

Authors:  D Marchaim; R Zaidenstein; T Lazarovitch; Y Karpuch; T Ziv; M Weinberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-05       Impact factor: 3.267

7.  Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes.

Authors:  A Abbo; Y Carmeli; S Navon-Venezia; Y Siegman-Igra; M J Schwaber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

8.  Validation of a prognostic score in critically ill patients undergoing transport.

Authors:  J F Bion; S A Edlin; G Ramsay; S McCabe; I M Ledingham
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-17

9.  International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

Review 10.  Treatment options for multidrug-resistant Acinetobacter species.

Authors:  Jacob Gilad; Yehuda Carmeli
Journal:  Drugs       Date:  2008       Impact factor: 9.546
View more
  16 in total

1.  K2 Capsule Depolymerase Is Highly Stable, Is Refractory to Resistance, and Protects Larvae and Mice from Acinetobacter baumannii Sepsis.

Authors:  Hugo Oliveira; Ana Mendes; Alexandra G Fraga; Alice Ferreira; Andreia I Pimenta; Dalila Mil-Homens; Arsénio M Fialho; Jorge Pedrosa; Joana Azeredo
Journal:  Appl Environ Microbiol       Date:  2019-08-14       Impact factor: 4.792

2.  The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China.

Authors:  X Zhen; Y Chen; X Hu; P Dong; S Gu; Y Y Sheng; H Dong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-23       Impact factor: 3.267

3.  4-4-(Anilinomethyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-ylbenzoic acid derivatives as potent anti-gram-positive bacterial agents.

Authors:  Raj Kc Hansa; M M K Khan; M M Frangie; D F Gilmore; R S Shelton; A V Savenka; A G Basnakian; S L Shuttleworth; M S Smeltzer; M A Alam
Journal:  Eur J Med Chem       Date:  2021-04-04       Impact factor: 7.088

4.  Selectable Markers for Use in Genetic Manipulation of Extensively Drug-Resistant (XDR) Acinetobacter baumannii HUMC1.

Authors:  Brian M Luna; Amber Ulhaq; Jun Yan; Paul Pantapalangkoor; Travis B Nielsen; Bryan W Davies; Luis A Actis; Brad Spellberg
Journal:  mSphere       Date:  2017-04-26       Impact factor: 4.389

5.  Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis.

Authors:  Lei Zha; Lingling Pan; Jun Guo; Neil French; Elmer V Villanueva; Boris Tefsen
Journal:  Adv Ther       Date:  2020-01-31       Impact factor: 3.845

Review 6.  Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities.

Authors:  Muhammad Asif; Iqbal Ahmad Alvi; Shafiq Ur Rehman
Journal:  Infect Drug Resist       Date:  2018-08-21       Impact factor: 4.003

7.  Clinical investigation of nosocomial infections in adult patients after cardiac surgery.

Authors:  Zhengqin Liu; Xiquan Zhang; Qian Zhai
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

8.  The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system.

Authors:  Dunja Said; Niklas Willrich; Olaniyi Ayobami; Ines Noll; Tim Eckmanns; Robby Markwart
Journal:  Antimicrob Resist Infect Control       Date:  2021-03-01       Impact factor: 4.887

9.  The role of the type VI secretion system vgrG gene in the virulence and antimicrobial resistance of Acinetobacter baumannii ATCC 19606.

Authors:  Jianfeng Wang; Zhihui Zhou; Fang He; Zhi Ruan; Yan Jiang; Xiaoting Hua; Yunsong Yu
Journal:  PLoS One       Date:  2018-02-02       Impact factor: 3.240

10.  Genomic analysis reveals high virulence and antibiotic resistance amongst phage susceptible Acinetobacter baumannii.

Authors:  Udomluk Leungtongkam; Rapee Thummeepak; Thawatchai Kitti; Kannipa Tasanapak; Jintana Wongwigkarn; Kathryn M Styles; Elizabeth M H Wellington; Andrew D Millard; Antonia P Sagona; Sutthirat Sitthisak
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.